This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
Next week HCS Pharma will be present both at Forum Labo Paris (26th-28th March ) and at SCMC congress in Lille (28-29th March)! In Forum Labo we will have our own stand in the Lab’StartUp Read more…
Victoria has joined us for a six-month internship in collaboration with the University of Technology of Compiègne. She will develop a liver biochip, using the BIOMIMESYS® Liver hydroscaffold. Victoria obtained her bachelor’s degree in Cellular Read more…
Skin commensals are crucial in the maintenance of the epithelial barrier function, regulation of the host immune system, and prevent invasion of other pathogenic microbes. In this article, published in September 2018, Burmeister et al Read more…
The neurovasculaire unit (NVU) is composed of brain microvascular endothelial cells (BMECs) that form the Blood-Brain-Barrier (BBB), pericytes, neurons and glial cells. It regulates substance transport between blood and brain. BBB and NVU dysfonctions are Read more…
The first version of BIOMIMESYS Brain allows to form neurospheres. We now developped a new version of BIOMIMESYS Brain, which allows to form neuronal networks. This version have a higher porosity than BIOMIMESYS Brain (Neurosphere), Read more…
After a bachelor of science in biology, Solenne has been graduated with a two-year diploma “DUT Génie Biologique”, specialized in biological and biochemistry analysis. Afterwards, she wenty on with a professional bachelor’s degree dealing with Read more…
Jean-Baptise obtained his Master’s degree in Cellular and Molecular Biology at Paris-Sorbonne University in 2018 after a six-month internship with us. He focused on the development of a human microbiota model in collaboration with the Read more…
Our CEO, Nathalie is the Chairwoman of the session “ Next Generation High-Content Bioimaging – Phenotypic Discovery” (Track 3 – session 2) at next SLAS Barcelona event. This event will bring together more than 1,000 Read more…
BIOMIMESYS® Oncology is mostly composed of hyaluronic acid (HA), biofunctionnalized with undenaturated collagen I. HA, by interacting with its binding proteins (CD44, RHAMM, ICAM-1), is an active participant in inflammatory, angiogenic, fibrotic and cancer-promoting processes Read more…
We were really happy to participate in SLAS2019 in Washington last week. In addition to spending a few relaxing days in Washington, we enjoyed the warm welcome of the US team of Molecular Devices. We Read more…
HCS Pharma is one of the winner of the Lab’StartUp village, organized by Forum Labo! As such, we have won a stand in the heart of the forum (March 26-28, 2019)… Thanks a lot to Read more…
Extracellular matrix (ECM) is known to have an influence on physiological processes and on tumour progression: ECM properties (composition, stiffness) modulate cell proliferation, migration, invasion and epithelial-to-mesenchymal transition (EMT). For example, EMT is inhibited by Read more…
Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy. What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ? View and download on Read more…
Last week we attend the 19th “Journées Européenes de Dermocosmetologie”. This year symposium was about “Intercellular exchanges in cutaneous tissues: which prospects in dermocosmetology for fragile skins ?” and we were very impressed by the Read more…
Many news have been published since 2 or 3 years about Artificial Intelligence (AI) and Machine Learning / Deep Learning use in picture analysis. Lastly, Microsoft published an astonishing article where they explained that this Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.